Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection

Viral Immunology

Volumn 25, Issue 1, 2012, Pages 37-44

  Peña, José ^a   Frías, Mario ^a   Castro Orgaz, Laura ^a   González, Rafael ^a   García, Felipe ^b   Gallart, Teresa ^b   Gatell, Jose María ^b   Plana, Montserrat ^b  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD56 ANTIGEN; DENDRITIC CELL VACCINE; NATURAL KILLER CELL RECEPTOR;

ARTICLE; CELL SUBPOPULATION; CLINICAL ARTICLE; CYTOLYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFLAMMATION; INNATE IMMUNITY; NATURAL KILLER CELL; TREATMENT OUTCOME; VIRUS LOAD;

AIDS VACCINES; ANTIGENS, CD56; DENDRITIC CELLS; DOUBLE-BLIND METHOD; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; IMMUNIZATION; KILLER CELLS, NATURAL; MALE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84856754580     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0044     Document Type: Article

References (49)

1. Ahmad A and Menezes J: Antibody-dependent cellular cytotoxicity in HIV infections. FASEB J 1996;10:258-266. (Pubitemid 26079945)
2. Alter G, and Altfeld M: NK cells in HIV-1 infection: evidence for their role in the control of HIV-1 infection. J Intern Med 2009;265:29-42.
3. Altfeld M, Fadda L, Frleta D, and Bhardwaj N: DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol 2011;11:176-186.
4. Autran B, Debre P, Walker B, and Katlama C: Therapeutic vaccines against HIV need international partnerships. Nat Rev Immunol 2003;3:503-508. (Pubitemid 37339190)
5. Banchereau J and Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245-252. (Pubitemid 28155090)
6. Banchereau J, Briere F, Caux C, et al.: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811. (Pubitemid 30365397)
7. Bellon T, Kitzig F, Sayos J, and Lopez-Botet M: Mutational analysis of immunoreceptor tyrosine-based inhibition motifs of the Ig-like transcript 2 (CD85j) leukocyte receptor. J Immunol 2002;168:3351-3359. (Pubitemid 34250398)
8. Berger EA: HIV entry and tropism: the chemokine receptor connection. AIDS 1997;11(Suppl A):S3-S16.
9. Bjorkstrom NK, Ljunggren HG, and Sandberg JK: CD56 negative NK cells: origin, function, and role in chronic viral disease. Trends Immunol 2010;31:401-406.
10. Bluman EM, Bartynski KJ, Avalos BR, and Caligiuri MA: Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocytederived cytokines. J Clin Invest 1996;97:2722-2727. (Pubitemid 26197715)
11. Borrego F, Kabat J, Kim DK, et al.: Structure and function of major histocompatibility complex (MHC) class I specific receptors expressed on human natural killer (NK) cells. Mol Immunol 2002;38:637-660. (Pubitemid 34168194)
12. Brenner BG, Gryllis C, and Wainberg MA: Role of antibodydependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. J Leukoc Biol 1991;50:628-640.
13. Brunetta E, Hudspeth KL, and Mavilio D: Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. J Leukoc Biol 2010;88:1119-1130.
14. Carcelain G, Debre P, and Autran B: Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Curr Opin Immunol 2001;13:483-488. (Pubitemid 32728483)
15. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, and Riddler SA: Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008;15:284-292. (Pubitemid 352025534)
16. Cooper MA, Fehniger TA, Fuchs A, Colonna M, and Caligiuri MA: NK cell and DC interactions. Trends Immunol 2004;25:47-52. (Pubitemid 38032807)
17. Choe H, Farzan M, Sun Y, et al.: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996;85:1135-1148. (Pubitemid 26231178)
18. Chung AW, Navis M, Isitman G, et al.: Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 2011;24:171-175.
19. Dorrell L: Therapeutic immunization for the control of HIV-1: where are we now? Int J STD AIDS 2006 17 436-441; quiz 442.
20. Fauci AS, Mavilio D, and Kottilil S: NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol 2005;5:835-843. (Pubitemid 41581665)
21. Fehniger TA, Herbein G, Yu H, Para MI, Bernstein ZP, O'Brien WA, and Caligiuri MA: Natural killer cells from HIV-1 + patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998;161:6433-6438. (Pubitemid 28536022)
22. Fernandez NC, Flament C, Crepineau F, Angevin E, Vivier E, and Zitvogel L: Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw 2002;13:17-27. (Pubitemid 34535568)
23. Forte P, Pazmany L, Matter-Reissmann UB, Stussi G, Schneider MK, and Seebach JD: HLA-G inhibits rolling adhesion of activated human NK cells on porcine endothelial cells. J Immunol 2001;167:6002-6008. (Pubitemid 33062798)
24. Garcia F, Plana M, Vidal C, et al.: Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999;13:F79-F86. (Pubitemid 29408440)
25. Garcia F, Lejeune M, Climent N, et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J Infect Dis 2005;191:1680-1685. (Pubitemid 40656756)
26. Garcia F, Climent N, Assoumou L, et al.: A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis 2011;203:473-478.
27. Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, Alaeus A, and Sandberg JK: Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 2008;128:46-56.
28. Hong HS, Eberhard JM, Keudel P, et al.: Phenotypically and functionally distinct subsets contribute to the expansion of CD56-/CD16 + natural killer cells in HIV infection. AIDS 2010;24:1823-1834.
29. Kottilil S, Chun TW, Moir S, et al.: Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis 2003;187:1038-1045. (Pubitemid 36399345)
30. Kottilil S, Shin K, Planta M, et al.: Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. J Infect Dis 2004;189: 1193-1198. (Pubitemid 38457243)
31. LarssonM, Fonteneau JF, and Bhardwaj N: Cross-presentation of cell-associated antigens by dendritic cells. Curr Top Microbiol Immunol 2003;276:261-275. (Pubitemid 36538356)
32. Letvin NL and Walker BD: Immunopathogenesis and immunotherapy in AIDS virus infections. Nat Med 2003;9:861-866. (Pubitemid 36889927)
33. Lima M, Almeida J, Montero AG, et al.: Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56-/+ dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004;165:1117-1127. (Pubitemid 39297719)
34. Lin SJ, Roberts RL, Ank BJ, Nguyen QH, Thomas EK, and Stiehm ER: Effect of interleukin (IL)-12 and IL-15 on activated natural killer (ANK) and antibody-dependent cellular cytotoxicity (ADCC) in HIV infection. J Clin Immunol 1998; 18:335-345. (Pubitemid 28467551)
35. Lozano J M, Gonzalez R, Luque J, Frias M, Rivero A, and Pena J: CD8( + )HLA-G( + ) regulatory T cells are expanded in HIV-1-infected patients. Viral Immunol 2009;22:463-465.
36. Lu W, Arraes LC, Ferreira WT, and Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med 2004;10:1359-1365. (Pubitemid 40022718)
37. Luque J, Lozano JM, Garcia-Jurado G, Soriano-Sarabia N, et al.: NK-associated regulatory receptors in a structured HAART interruption of HIV-1-positive individuals. AIDS Res Hum Retroviruses 2008;24:1037-1042.
38. Mavilio D, Benjamin J, Daucher M, et al.: Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA 2003;100:15011-15016. (Pubitemid 37518008)
39. Mavilio D, Lombardo G, Benjamin J, et al.: Characterization of CD56-/CD16 + natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA 2005;102:2886-2891. (Pubitemid 40299886)
40. Monsivais-Urenda A, Nino-Moreno P, Abud-Mendoza C, Baranda L, Layseca-Espinosa E, Lopez-Botet M, and Gonzalez-Amaro R: Analysis of expression and function of the inhibitory receptor ILT2 (CD85j/LILRB1/LIR-1) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus (SLE). J Autoimmun 2007; 29:97-105. (Pubitemid 47385109)
41. Montaner LJ, Crowe SM, Aquaro S, Perno CF, Stevenson M, and Collman RG: Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs. J Leukoc Biol 2006;80:961-964. (Pubitemid 44646301)
42. Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, and Moretta L: Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol 2005;26:668-675. (Pubitemid 41628200)
43. Oliva A, Kinter AL, Vaccarezza M, et al.: Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest 1998;102:223-231. (Pubitemid 28323849)
44. Saverino D, Ghiotto F, Merlo A, et al.: Specific recognition of the viral protein UL18 by CD85j/LIR-1/ILT2 on CD8 + T cells mediates the non-MHC-restricted lysis of human cytomegalovirus- infected cells. J Immunol 2004;172:5629-5637. (Pubitemid 38542066)
45. Sirianni MC, Mezzaroma I, Aiuti F, and Moretta A: Analysis of the cytolytic activity mediated by natural killer cells from acquired immunodeficiency syndrome patients in response to phytohemagglutinin or anti-CD16 monoclonal antibody. Eur J Immunol 1994;24:1874-1878. (Pubitemid 24237561)
46. Tarazona R, DelaRosa O, Casado JG, Torre-Cisneros J, Villanueva JL, Galiani MD, Pena J, and Solana R: NK-associated receptors on CD8 T cells from treatment-naive HIV-infected individuals: defective expression of CD56. AIDS 2002;16: 197-200. (Pubitemid 34118566)
47. Terzieva V: Regulatory T cells and HIV-1 infection. Viral Immunol 2008;21:285-291.
48. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, and Lanier LL: Cross-talk between activated human NK cells and CD4 + T cells via OX40-OX40 ligand interactions. J Immunol 2004;173:3716-3724. (Pubitemid 39280732)
49. Zingoni A, Sornasse T, Cocks BG, Tanaka Y, Santoni A, and Lanier LL: NK cell regulation of T cell-mediated responses. Mol Immunol 2005;42:451-454. (Pubitemid 39655952)